Diabetes management
===================


Information was omitted from Table 1 on page [596](http://www.ccjm.org/lookup/doi/10.3949/ccjm.86a.18031) of the article, Makin V, Lansang MC. Diabetes management: beyond hemoglobin A1c (Cleve Clin J Med 2019; 86(9):595–600, doi:10.3949/ccjm.86a.18031.

View this table:
[TABLE 1](http://www.ccjm.org/content/86/11/760/T1)

TABLE 1 
Advantages of selected type 2 diabetes drugs

The sodium-glucose cotransporter 2 (SGLT2) inhibitors pose a low risk of hypoglyemia, and that should have been noted in the table. The corrected table appears below and online.

*   © 2019 The Cleveland Clinic Foundation. All Rights Reserved.